Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy

Hexamethylene bisacetamide-inducible protein 1 (HEXIM1) is best known as the inhibitor of positive transcription elongation factor b (P-TEFb) and is recently identified as a novel positive regulator of p53. We previously showed the basic region (BR) of HEXIM1 mediates the binding of HEXIM1 to a nucl...

Descripción completa

Detalles Bibliográficos
Autores principales: Neo, Shu Hui, Lew, Qiao Jing, Koh, Ser Mei, Zheng, Lu, Bi, Xuezhi, Chao, Sheng-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868700/
https://www.ncbi.nlm.nih.gov/pubmed/26734838
http://dx.doi.org/10.18632/oncotarget.6794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868700/
https://www.ncbi.nlm.nih.gov/pubmed/26734838
http://dx.doi.org/10.18632/oncotarget.6794

Ejemplares similares